Living donor liver transplantation for hepatocellular carcinoma
Objective Living donor liver transplantation (LDLT) may represent a valid therapeutic option allowing several advantages for patients affected by hepatocellular carcinoma (HCC) awaiting orthotopic liver transplantation (OLT). However, some reports in the literature have demonstrated worse long-term...
محفوظ في:
| المؤلف الرئيسي: | |
|---|---|
| مؤلفون آخرون: | , , , , , , , , |
| التنسيق: | article |
| منشور في: |
2009
|
| الوصول للمادة أونلاين: | http://hdl.handle.net/10725/14059 https://doi.org/10.1016/j.transproceed.2009.03.022 http://libraries.lau.edu.lb/research/laur/terms-of-use/articles.php https://www.sciencedirect.com/science/article/pii/S0041134509004096 |
| الوسوم: |
إضافة وسم
لا توجد وسوم, كن أول من يضع وسما على هذه التسجيلة!
|
| _version_ | 1864513468851290112 |
|---|---|
| author | Di Sandro, S. |
| author2 | Slim, A. O. Giacomoni, A. Lauterio, A. Mangoni, I. Aseni, P. Pirotta, V. Aldumour, A. Mihaylov, P. De Carlis, L. |
| author2_role | author author author author author author author author author |
| author_facet | Di Sandro, S. Slim, A. O. Giacomoni, A. Lauterio, A. Mangoni, I. Aseni, P. Pirotta, V. Aldumour, A. Mihaylov, P. De Carlis, L. |
| author_role | author |
| dc.creator.none.fl_str_mv | Di Sandro, S. Slim, A. O. Giacomoni, A. Lauterio, A. Mangoni, I. Aseni, P. Pirotta, V. Aldumour, A. Mihaylov, P. De Carlis, L. |
| dc.date.none.fl_str_mv | 2009 2022-10-13T12:17:22Z 2022-10-13T12:17:22Z 2022-10-13 |
| dc.identifier.none.fl_str_mv | 0041-1345 http://hdl.handle.net/10725/14059 https://doi.org/10.1016/j.transproceed.2009.03.022 Di Sandro, S., Slim, A. O., Giacomoni, A., Lauterio, A., Mangoni, I., Aseni, P., ... & De Carlis, L. (2009, May). Living donor liver transplantation for hepatocellular carcinoma: long-term results compared with deceased donor liver transplantation. In Transplantation proceedings 41(4), 1283-1285. http://libraries.lau.edu.lb/research/laur/terms-of-use/articles.php https://www.sciencedirect.com/science/article/pii/S0041134509004096 |
| dc.language.none.fl_str_mv | en |
| dc.relation.none.fl_str_mv | Transplantation Proceedings |
| dc.rights.*.fl_str_mv | info:eu-repo/semantics/openAccess |
| dc.title.none.fl_str_mv | Living donor liver transplantation for hepatocellular carcinoma long-term results compared with deceased donor liver transplantation |
| dc.type.none.fl_str_mv | Article info:eu-repo/semantics/publishedVersion info:eu-repo/semantics/article |
| description | Objective Living donor liver transplantation (LDLT) may represent a valid therapeutic option allowing several advantages for patients affected by hepatocellular carcinoma (HCC) awaiting orthotopic liver transplantation (OLT). However, some reports in the literature have demonstrated worse long-term and disease-free survivals among patients treated by LDLT than deceased donor liver transplantation (DDLT) for HCC. Herein we have reported our long-term results comparing LDLT with DDLT for HCC. Patients and Methods Among 179 patients who underwent OLT from January 2000 to December 2007, 25 (13.9%) received LDLT with HCC 154 (86.1%) received DDLT. Patients were selected based on the Milan criteria. Transarterial chemoembolization, radiofrequency ablation, percutaneous alcoholization, or liver resection was applied as a downstaging procedure while on the waiting list. Patients with stage II HCC were proposed for LDLT. Results The overall 3- and 5-year survival rates were 77.3% and 68.7% versus 82.8% and 76.7% for LDLT and DDLT recipients, respectively, with no significant difference by the log-rank test. Moreover, the 3- and 5-year recurrence-free survival rates were 95.5% and 95.5% (LDLT) versus 90.5% and 89.4% (DDLT; P = NS). Conclusions LDLT guarantees the same long-term results as DDLT where there are analogous selection criteria for candidates. The Milan criteria remain a valid tool to select candidates for LDLT to achieve optimal long-term results. |
| eu_rights_str_mv | openAccess |
| format | article |
| id | LAURepo_516740f5cdc12e830fde69164fb49fce |
| identifier_str_mv | 0041-1345 Di Sandro, S., Slim, A. O., Giacomoni, A., Lauterio, A., Mangoni, I., Aseni, P., ... & De Carlis, L. (2009, May). Living donor liver transplantation for hepatocellular carcinoma: long-term results compared with deceased donor liver transplantation. In Transplantation proceedings 41(4), 1283-1285. |
| language_invalid_str_mv | en |
| network_acronym_str | LAURepo |
| network_name_str | Lebanese American University repository |
| oai_identifier_str | oai:laur.lau.edu.lb:10725/14059 |
| publishDate | 2009 |
| repository.mail.fl_str_mv | |
| repository.name.fl_str_mv | |
| repository_id_str | |
| spelling | Living donor liver transplantation for hepatocellular carcinomalong-term results compared with deceased donor liver transplantationDi Sandro, S.Slim, A. O.Giacomoni, A.Lauterio, A.Mangoni, I.Aseni, P.Pirotta, V.Aldumour, A.Mihaylov, P.De Carlis, L.Objective Living donor liver transplantation (LDLT) may represent a valid therapeutic option allowing several advantages for patients affected by hepatocellular carcinoma (HCC) awaiting orthotopic liver transplantation (OLT). However, some reports in the literature have demonstrated worse long-term and disease-free survivals among patients treated by LDLT than deceased donor liver transplantation (DDLT) for HCC. Herein we have reported our long-term results comparing LDLT with DDLT for HCC. Patients and Methods Among 179 patients who underwent OLT from January 2000 to December 2007, 25 (13.9%) received LDLT with HCC 154 (86.1%) received DDLT. Patients were selected based on the Milan criteria. Transarterial chemoembolization, radiofrequency ablation, percutaneous alcoholization, or liver resection was applied as a downstaging procedure while on the waiting list. Patients with stage II HCC were proposed for LDLT. Results The overall 3- and 5-year survival rates were 77.3% and 68.7% versus 82.8% and 76.7% for LDLT and DDLT recipients, respectively, with no significant difference by the log-rank test. Moreover, the 3- and 5-year recurrence-free survival rates were 95.5% and 95.5% (LDLT) versus 90.5% and 89.4% (DDLT; P = NS). Conclusions LDLT guarantees the same long-term results as DDLT where there are analogous selection criteria for candidates. The Milan criteria remain a valid tool to select candidates for LDLT to achieve optimal long-term results.Published2022-10-13T12:17:22Z2022-10-13T12:17:22Z20092022-10-13Articleinfo:eu-repo/semantics/publishedVersioninfo:eu-repo/semantics/article0041-1345http://hdl.handle.net/10725/14059https://doi.org/10.1016/j.transproceed.2009.03.022Di Sandro, S., Slim, A. O., Giacomoni, A., Lauterio, A., Mangoni, I., Aseni, P., ... & De Carlis, L. (2009, May). Living donor liver transplantation for hepatocellular carcinoma: long-term results compared with deceased donor liver transplantation. In Transplantation proceedings 41(4), 1283-1285.http://libraries.lau.edu.lb/research/laur/terms-of-use/articles.phphttps://www.sciencedirect.com/science/article/pii/S0041134509004096enTransplantation Proceedingsinfo:eu-repo/semantics/openAccessoai:laur.lau.edu.lb:10725/140592022-10-13T12:25:28Z |
| spellingShingle | Living donor liver transplantation for hepatocellular carcinoma Di Sandro, S. |
| status_str | publishedVersion |
| title | Living donor liver transplantation for hepatocellular carcinoma |
| title_full | Living donor liver transplantation for hepatocellular carcinoma |
| title_fullStr | Living donor liver transplantation for hepatocellular carcinoma |
| title_full_unstemmed | Living donor liver transplantation for hepatocellular carcinoma |
| title_short | Living donor liver transplantation for hepatocellular carcinoma |
| title_sort | Living donor liver transplantation for hepatocellular carcinoma |
| url | http://hdl.handle.net/10725/14059 https://doi.org/10.1016/j.transproceed.2009.03.022 http://libraries.lau.edu.lb/research/laur/terms-of-use/articles.php https://www.sciencedirect.com/science/article/pii/S0041134509004096 |